Novo investors call for dealmaking and new drugs
Posted by MarketsWire
Novo Nordisk investors are pressing the company to diversify and develop new drugs as it prepares to face shareholders, which could affect its growth prospects. Retail investors may want to watch whether management responds with credible plans and how those plans could influence the company’s future performance. Do you think Novo Nordisk should focus more on dealmaking, new drugs, or its existing treatments?